CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...
In a regulatory filing, Scholar Rock ( SRRK) CEO Jay Backstrom disclosed the sale of 18,372 common shares of the company on February 18 at a price of $36.829 per share. Published first on TheFly – the ...
Scholar Rock has a 52 week low of $6.76 and a 52 week high of $46.98. The firm has a 50 day simple moving average of $41.89 and a 200 day simple moving average of $28.17. Get Scholar Rock alerts: ...
Shares of Scholar Rock Holding Co. (NASDAQ:SRRK – Get Free Report) have been assigned a consensus rating of “Buy” from the ...
Mo Qatanani, Chief Scientific Officer at Scholar Rock Holding Corp (NASDAQ:SRRK), recently sold shares worth approximately $2.56 million. The transactions occurred on February 19, 2025 ...
China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug Future of Healthcategory· November 20, 2024 Scholar Rock's experimental drug achieved its main target in a ...
Shares in Scholar Rock have gone into overdrive after the biotech reported positive phase 3 results with apitegromab in patients with spinal muscular atrophy (SMA), setting up regulatory filings ...
Some doctors say drugs that improve muscle mass could benefit older or infirm people at greater risk of falls and fractures.
About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results